RVL Pharmaceuticals plc (RVLP)

Athyrium Provides Capital to Support Long-Term Growth and Exchanges Outstanding Debt into Equity of Certain Reorganized Entities

RVL Pharmaceuticals (NASDAQ: RVLP ) stock is rising higher on Wednesday even without any news from the specialty pharmaceutical company. Shares of RVL Pharmaceuticals stock are climbing today despite the company not putting out any new press releases.

Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries to Continue as They Pursue Strategic Plan RVLP Ordinary Shares Expected to be Cancelled BRIDGEWATER, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (“RVL” or “the Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy eyelid, in adults, today announced that certain of its U.S. operating subsidiaries, RevitaLid Pharmaceutical Corp., RVL Pharmaceuticals, Inc. and RVL Pharmacy, LLC (the “RVL Subsidiaries”), have reached an agreement with their sole secured lenders, funds managed by Athyrium Capital Management (“Athyrium”), and other key stakeholders, to effectuate a change of control transaction through prepackaged bankruptcy cases commenced in the United States Bankruptcy Court for the District of Delaware today (the “Reorganization”).

RVL Pharmaceuticals (NASDAQ: RVLP ) stock is climbing higher on Friday despite a lack of news from the specialty pharmaceutical company. There aren't any new press releases of filings with the Securities and Exchange Commission (SEC) that explain why the shares are up today.

BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 25 th Annual Global Investment Conference in New York City as follows:

BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, today announced that it has entered into definitive agreements for the purchase and sale of 11,870,846 of its ordinary shares (or ordinary share equivalents in lieu thereof) at a purchase price of $0.4212 per ordinary share (or ordinary share equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The Company also agreed to issue to the investors unregistered series A-1 warrants to purchase up to 11,870,846 ordinary shares and unregistered series A-2 warrants to purchase up to 11,870,846 ordinary shares. The series A-1 warrants have an exercise price of $0.4212 per share, will be exercisable beginning on the effective date of shareholder approval of the issuance of the shares upon exercise of the series A-1 warrants, and will expire five years following the date of shareholder approval. The series A-2 warrants have an exercise price of $0.4212 per share, will be exercisable beginning on the effective date of shareholder approval of the issuance of the shares upon exercise of the series A-2 warrants, and will expire eighteen months following the date of shareholder approval. The closing of the offering is expected to occur on or about August 18, 2023, subject to the satisfaction of customary closing conditions.

-- UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity -- -- Executed financing amendment with Athyrium, which, subject to certain conditions, would provide meaningful flexibility as part of our ongoing strategy to invest in UPNEEQ and drive growth --

-- Conference call to be held Monday, August 14, 2023, at 8:30 a.m. ET -- -- Conference call to be held Monday, August 14, 2023, at 8:30 a.m. ET --

Today we take our first look at RVL Pharmaceuticals plc, a small ocular-focused concern. RVL Pharmaceuticals plc recently launched the first and only FDA-approved ophthalmic solution to treat low-lying eyelids in adults.

RVL Pharmaceuticals plc (NASDAQ:RVLP ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Lisa Wilson – Investor Relations Brian Markison – Chief Executive Officer JD Schaub – Chief Operating Officer Mike DePetris – Interim Chief Financial Officer Conference Call Participants Louise Chen – Cantor Fitzgerald Douglas Tsao – H.C Wainwright John Vandermosten – Zacks Operator Good day, everyone. My name is Chelsea, and I'll be your conference operator.

RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 20.83% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

RVL Pharmaceuticals plc (NASDAQ:RVLP ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Lisa Wilson - IR Brian Markison - CEO Mike DePetris - Interim CFO JD Schaub - COO Conference Call Participants Louise Chen - Cantor Douglas Tsao - H.C Wainwright Michaela Diverio - Barclays Operator Good day and thank you for standing by. Welcome to the RVL Pharmaceuticals Second Quarter 2022 Earnings Call.

BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at two upcoming conferences as follows:

RVL Pharmaceuticals plc (NASDAQ:RVLP ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Lisa Wilson – Investor Relations Brian Markison – Chief Executive Officer Mike DePetris – Interim Chief Financial Officer JD Schaub – Chief Operational Officer Conference Call Participants Douglas Tsao – H.C Wainwright Louise Chen – Cantor Greg Fraser – Truist Securities Balaji Prasad – Barclays Operator Good morning everyone. My name is Bertney and I will be your conference operator.

RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 48% and 197.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

RVL Pharmaceuticals plc (RVLP) CEO Brian Markison on Q4 2021 Results - Earnings Call Transcript